influenza
viru
iav
import
human
viral
pathogen
respons
period
human
pandem
well
season
influenza
result
substanti
human
morbid
mortal
worldwid
financi
burden
annual
vaccin
current
avail
control
infect
human
howev
mutat
haemagglutinin
ha
neuraminidas
na
protein
circul
virus
easili
escap
surveil
host
immun
system
specif
antivir
drug
avail
prophylaxi
therapeut
treatment
individu
infect
iav
two
class
food
drug
administr
fda
drug
current
use
treatment
iav
infect
includ
na
inhibitor
oseltamivir
zanamivir
matrix
protein
ion
channel
inhibitor
amantadin
rimantadin
howev
resist
develop
seriou
problem
antivir
drug
particularli
target
viral
protein
continu
undergo
high
frequenc
antigen
drift
human
influenza
virus
includ
pandem
current
resist
amantadinerimantadin
oseltamivir
therefor
identif
novel
antivir
target
develop
antivir
drug
treatment
influenza
viru
infect
imper
viral
nucleoprotein
np
influenza
viru
recent
identifi
target
develop
antivir
drug
influenza
np
major
compon
viral
ribonucleoprotein
vrnp
complex
abundantli
express
infect
multipl
function
vrnp
complex
util
nuclear
local
signal
nlss
within
np
nuclear
import
cellular
nuclear
import
pathway
also
support
previou
report
late
stage
infect
np
nuclear
export
protein
nep
matrix
protein
mediat
transport
newli
assembl
vrnp
complex
nucleu
cytoplasm
overal
np
sever
conform
activ
conserv
among
influenza
virus
cellular
equival
thu
np
ideal
target
develop
commerci
drug
studi
aim
identifi
new
compound
screen
librari
consist
compound
use
infect
assay
identifi
compound
inhibit
iav
replic
show
low
cell
toxic
vitro
vivo
shown
inhibit
viral
polymeras
activ
influenza
virus
nuclear
export
np
furthermor
dock
analysi
surfac
plasmon
reson
spr
analysi
assay
show
bind
small
pocket
structur
np
molecul
chemic
librari
structur
divers
small
molecul
compound
chemdiv
purchas
j
k
chemic
compani
shanghai
china
puriti
synthes
institut
medicin
chemistri
sysu
stock
dimethyl
sulphoxid
dmso
oseltamivir
phosphat
os
purchas
selleck
compani
shanghai
china
stock
solut
prepar
dmso
leptomycin
b
lmb
purchas
cell
signal
technolog
beverli
usa
dissolv
ethanol
etoh
lipopolysaccharid
lp
purchas
st
loui
mo
usa
stock
solut
prepar
water
human
lung
carcinoma
cell
human
embryon
kidney
cell
canin
kidney
mdck
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
lo
angel
ca
usa
supplement
foetal
bovin
serum
fb
gibco
influenza
viru
viru
viru
use
viru
purchas
american
type
cultur
collect
atcc
viru
stock
prepar
previous
describ
eight
fragment
influenza
viru
vrnp
gene
fragment
viru
synthes
invitrogen
fragment
viru
virus
clone
vector
separ
previous
describ
plasmid
mutant
plasmid
deriv
influenza
viru
clone
vector
separ
antibodi
use
report
includ
mous
monoclon
mbl
japan
rabbit
polyclon
mbl
rabbit
polyclon
proteintech
group
chicago
il
usa
rabbit
polyclon
abcam
cambridg
usa
rabbit
polyclon
proteintech
group
mous
monoclon
bd
bioscienc
san
jose
ca
usa
antibodi
rabbit
polyclon
sino
biolog
china
influenza
viru
viru
rescu
use
eight
revers
genet
system
describ
previous
canin
kidney
mdck
cell
seed
onto
plate
incub
dmem
contain
synthes
librari
compound
use
tecan
freedom
tecan
schweiz
final
concentr
column
receiv
dmso
instead
compound
cell
infect
influenza
viru
multipl
infect
moi
hr
pi
celltit
aqueou
one
solut
reagent
electron
coupl
reagent
ad
well
recommend
manufactur
cultur
hr
cell
viabil
determin
measur
absorb
wavelength
nm
screen
assay
perform
twice
studi
viru
activ
test
accord
previou
report
viru
titr
determin
plaqu
assay
mdck
cell
previous
describ
briefli
cell
infect
influenza
viru
moi
hr
pi
medium
replac
dmem
contain
bsa
supernat
collect
hr
pi
measur
viru
titr
viru
titr
determin
plaqu
assay
mdck
cell
mdck
cell
seed
plate
use
infect
cell
grown
confluenc
mdck
cell
wash
salin
pb
infect
seri
dilut
virus
hr
viru
inocula
remov
cell
wash
pb
overlaid
agaros
medium
dmem
contain
bsa
agaros
plate
settl
min
agaros
medium
becam
solid
follow
cultur
upsid
cell
cultur
hr
visibl
plaqu
count
inhibitori
concentr
determin
count
number
plaqu
cell
toxic
assay
determin
mt
assay
accord
manufactur
instruct
promega
madison
wi
previous
describ
data
shown
mean
deviat
sd
three
independ
experi
influenza
viru
minigenom
system
perform
previous
describ
data
shown
mean
sd
three
independ
experi
cell
lyse
lysi
buffer
min
lysat
collect
separ
previous
describ
band
immunoblot
indic
primari
antibodi
irdy
secondari
antibodi
lincoln
ne
usa
visual
odyssey
infrar
imag
system
rel
protein
express
level
analys
use
softwar
provid
odyssey
system
human
cell
seed
dish
transfect
variou
plasmid
indic
cell
untreat
treat
differ
amount
hr
pt
hr
pt
cell
lyse
lysi
buffer
lysat
taken
input
control
remain
lysat
incub
agaros
bead
hr
bead
wash
three
time
lysi
buffer
follow
western
blot
immunofluoresc
assay
ifa
perform
previous
describ
briefli
cell
fix
paraformaldehyd
permeabil
triton
subsequ
block
bsa
block
solut
stain
primari
antibodi
secondari
antibodi
cell
nuclei
stain
dapi
reagent
invitrogen
carlsbad
ca
usa
imag
obtain
leica
laser
scan
microscop
use
leica
softwar
wetzlar
germani
human
cell
transfect
plasmid
untreat
treat
cell
harvest
wash
pb
hr
pt
fraction
cytoplasm
nuclear
compon
perform
accord
manufactur
instruct
pari
millipor
usa
previous
describ
cell
transfect
differ
treatment
collect
fix
formaldehyd
analys
bd
lsr
cell
analyz
accord
manufactur
protocol
bd
previous
describ
crystal
structur
influenza
viru
nucleoprotein
download
rcsb
protein
data
bank
pdb
code
resolut
np
bind
assess
use
dock
ligand
receptor
structur
construct
use
ucsf
chimera
program
util
conduct
dock
differ
orient
gener
van
der
waal
electrostat
interact
obtain
ligand
bind
site
use
calcul
grid
score
use
molecular
visual
tool
pymol
pymol
molecular
graphic
system
version
seattl
usa
gener
surfac
np
help
spot
bind
site
interfac
np
assay
perform
use
biacor
instrument
ge
healthcar
amersham
uk
previous
describ
modif
biacor
sensor
chip
amin
coupl
kit
purchas
ge
healthcar
optim
ph
immobil
ph
first
determin
censor
chip
activ
inject
mgml
mm
acet
buffer
ph
min
residu
activ
group
surfac
block
inject
ethanolamin
hcl
min
differ
amount
dilut
dmso
inject
min
anim
experi
approv
ethic
committe
zhongshan
school
medicin
zssom
laboratori
anim
care
carri
strict
accord
guidelin
regul
laboratori
anim
center
zssom
sysu
guangzhou
china
assur
number
mice
studi
provid
via
standard
pellet
feed
water
procedur
perform
anaesthesia
induc
isofluran
rwd
life
scienc
co
ltd
shenzhen
china
treatment
effort
made
minim
suffer
mice
kill
rapid
last
weight
loss
loss
bodi
weight
day
observ
dissolv
dmso
dilut
corn
oil
final
concentr
mgml
dmso
dilut
corn
oil
taken
control
male
balbc
mice
approxim
g
use
experi
mice
intranas
infect
ten
lethal
dose
intraperiton
inject
twice
daili
mgkg
day
begin
hr
infect
respect
experi
mice
intraperiton
given
monotherapi
mgkg
mgkg
oseltamivir
phosphat
twice
daili
day
begin
hr
infect
respect
eight
mice
per
treatment
group
test
bodi
weight
surviv
rate
group
measur
daili
parallel
experi
five
mice
group
kill
day
pi
lung
remov
determin
viral
titr
use
plaqu
assay
experi
repeat
triplic
differ
bodi
weight
lung
viral
titr
group
compar
control
use
anova
analysi
surviv
rate
analys
test
data
consid
signific
p
p
p
total
rna
isol
perform
previous
describ
specif
primer
target
gene
gapdh
housekeep
control
mice
design
use
primer
base
correspond
gene
sequenc
protein
primer
sequenc
follow
data
shown
mean
sd
three
independ
experi
half
lung
liver
spleen
kidney
heart
mous
fix
formalin
embed
paraffin
stain
haematoxylin
eosin
h
e
histolog
analysi
slide
random
read
blindli
examin
tissu
damag
inflammatori
cellular
infiltr
lung
patholog
score
rang
previou
report
data
analys
use
graphpad
prism
softwar
la
jolla
ca
usa
student
anova
test
use
determin
signific
statist
data
data
consid
signific
p
p
p
discov
novel
compound
mdck
influenza
infect
screen
perform
briefli
chemic
librari
structur
divers
small
molecul
compound
appli
screen
mdck
cell
infect
viru
multipl
infect
moi
pfu
perform
assay
among
hit
compound
identifi
seven
compound
exert
inhibitori
effect
concentr
among
hit
compound
show
highest
potenc
influenza
viru
plaqu
reduct
assay
pra
mdck
cell
infect
viru
chemic
structur
compound
shown
figur
use
plaqu
assay
inhibitori
concentr
mdck
cell
lower
fig
show
similar
level
antivir
activ
differ
iav
subtyp
includ
viru
viru
fig
furthermor
low
toxic
mdck
cell
cytotox
concentr
compound
fig
togeth
result
show
compound
significantli
inhibit
replic
iav
confirm
whether
np
direct
molecular
target
util
publish
crystal
structur
influenza
np
protein
data
bank
pdb
silico
dock
studi
unbias
predict
dock
analysi
search
potenti
dock
site
within
entir
np
monom
five
potenti
bind
site
identifi
fig
base
highest
bind
free
energi
bind
site
within
np
select
analysi
configur
best
bind
score
kcalmol
also
identifi
use
studi
fig
two
amino
acid
residu
hydrogen
bond
play
major
role
bind
np
fig
confirm
accuraci
bind
model
surfac
plasmon
reson
spr
experi
util
examin
whether
bind
mutant
np
protein
harbour
alanin
substitut
within
potenti
bind
site
mutant
spr
assay
indic
bound
mutant
kd
valu
respect
fig
although
remain
bind
mutant
np
protein
bind
affin
significantli
lower
np
protein
therebi
indic
two
residu
play
critic
role
interact
np
result
suggest
bind
np
mainli
amino
acid
residu
predict
silico
dock
analysi
bind
region
np
aa
involv
nuclear
export
np
therebi
indic
mechan
underli
nuclear
export
np
previou
studi
shown
nuclear
export
mediat
wherea
investig
whether
inhibitori
effect
nuclear
export
np
depend
nuclear
transport
pathway
examin
bind
endogen
np
presenc
absenc
bind
np
inhibit
manner
fig
result
indic
inhibit
bind
np
interact
ne
domain
np
addit
np
amino
acid
involv
interact
dock
model
show
partial
bound
amino
acid
involv
np
dimer
domain
examin
whether
induc
dissoci
perform
assay
incorpor
np
protein
fuse
differ
tag
previou
report
absenc
abl
bind
ha
agaros
bead
coupl
fig
howev
inhibit
bind
manner
suggest
also
inhibit
interact
taken
togeth
result
demonstr
inhibit
function
domain
oligomer
np
interact
test
vivo
efficaci
iav
infect
mice
inocul
intraperiton
inject
daili
differ
dose
mgkg
twice
per
day
five
day
begin
hr
infect
respect
fig
treatment
appar
protect
mice
morbid
lethal
fig
c
parallel
experi
mice
kill
group
pi
lung
isol
use
determin
viru
titr
plaqu
assay
fig
e
viru
load
lung
mice
significantli
lower
control
group
moreov
oseltamivir
phosphat
investig
antivir
activ
treat
togeth
oseltamivir
phosphat
although
less
effect
protect
mice
influenza
vivo
compar
oseltamivir
phosphat
oseltamivir
phosphat
result
even
lower
degre
weight
loss
higher
surviv
rate
treat
oseltamivir
phosphat
alon
fig
g
result
support
hypothesi
mechan
oseltamivir
phosphat
highli
variabl
better
vivo
effect
observ
administ
combin
oseltamivir
phosphat
also
significantli
reduc
viral
load
lung
fig
result
show
effect
protect
mice
influenza
infect
vivo
influenza
viru
infect
caus
sever
lung
patholog
associ
acut
lung
inflamm
exacerb
partli
host
immun
respons
viru
infect
cytokineschemokin
imped
influenza
pathogenesi
therefor
investig
effect
influenza
cytokinechemokin
express
vivo
mice
mock
infect
infect
viru
untreat
treat
mgkg
twice
daili
mice
kill
day
pi
lung
mice
collect
total
rna
extract
mrna
level
cytokin
involv
promot
inflamm
report
play
import
role
sever
iav
infect
lung
significantli
decreas
mice
compar
untreat
mice
fig
howev
treat
mice
lipopolysaccharid
lp
activ
alter
express
lung
indict
effect
express
cytokin
absenc
infect
fig
result
show
reduc
express
cytokin
associ
influenza
viru
infect
parallel
experi
lung
collect
day
pi
stain
h
e
histolog
evalu
treatment
allevi
inflamm
interstiti
epithelium
thicken
induc
iav
infect
fig
observ
impli
probabl
limit
spread
viru
lung
therebi
allevi
inflamm
line
figur
result
also
indic
inhibit
replic
iav
vivo
turn
allevi
inflammatori
level
patholog
induc
iav
overal
find
suggest
potent
effect
host
intens
immun
respons
induc
iav
present
studi
identifi
novel
compound
effici
inhibit
replic
influenza
viru
vitro
vivo
effici
protect
cell
differ
subtyp
influenza
viru
particular
abl
inhibit
replic
viru
rel
low
concentr
nm
vitro
furthermor
vivo
data
indic
reduc
express
cytokineschemokin
allevi
infiltr
inflamm
lung
caus
iav
infect
also
increas
surviv
rate
mice
prevent
bodi
weight
loss
due
iav
infect
result
suggest
effect
inhibit
iav
replic
reduc
viral
titr
vitro
vivo
turn
allevi
patholog
induc
iav
find
suggest
potent
effect
host
intens
immun
respons
induc
iav
therebi
render
promis
lead
compound
treatment
sever
influenza
vivo
oseltamivir
phosphat
augment
antivir
effect
suggest
inhibit
viral
replic
via
new
mechan
differ
oseltamivir
phosphat
investig
indic
block
nuclear
transport
vrnp
complex
nucleu
target
nuclear
export
np
three
ness
identifi
within
np
export
via
independ
transport
pathway
wherea
export
via
depend
bind
therefor
nuclear
retent
np
induc
may
due
disrupt
follow
pathway
target
within
np
ii
target
within
np
block
interact
np
iii
target
associ
protein
exclud
direct
target
util
plasmid
experi
aid
classic
host
protein
transport
nucleu
mainli
mediat
pathway
distribut
affect
wherea
classic
small
molecul
inhibitor
lmb
block
nuclear
export
aid
therefor
directli
inhibit
transport
pathway
lmb
explor
particular
bind
site
within
np
dock
analysi
incorpor
structur
within
np
perform
result
show
potenti
bind
site
within
np
small
pocket
includ
line
bind
model
investig
prove
directli
bind
np
disrupt
interact
np
moreov
dock
analysi
spr
assay
indic
aa
np
anoth
import
bind
site
line
result
inhibit
interact
reduc
polymeras
activ
impair
protein
synthesi
iav
taken
togeth
result
strongli
support
theori
np
target
drug
resist
seriou
problem
associ
influenza
treatment
caus
high
antigen
drift
shift
rate
discoveri
new
target
thu
focu
develop
new
therapeut
sequenc
analysi
indic
np
protein
among
differ
strain
iav
furthermor
target
site
within
np
highli
conserv
conserv
therebi
indic
broadli
inhibitori
potenc
variou
iav
strain
includ
replic
subtyp
polymeras
activ
subtyp
altern
challeng
drug
design
develop
avoid
occurr
seriou
side
effect
influenza
np
protein
play
crucial
role
viral
life
cycl
activ
assembl
stabil
nuclear
transport
vrnp
complex
reli
function
np
therefor
np
highli
conserv
function
restrict
protein
thu
render
promis
specif
target
drug
design
nucleoprotein
np
recent
consid
novel
target
drug
design
recent
small
compound
target
function
domain
within
np
identifi
pocket
target
compound
report
surround
three
differ
domain
name
rna
bind
groov
np
dimer
interfac
present
studi
bind
pocket
within
np
studi
similar
base
similar
function
differ
chemic
structur
conclud
bind
pocket
indispens
pocket
np
would
ideal
antivir
target
side
studi
shown
inhibit
iav
replic
vitro
vivo
effici
one
hit
compound
identifi
via
screen
could
optim
becom
potent
inhibitor
summari
novel
compound
identifi
high
potenc
inhibit
iav
replic
vitro
vivo
disrupt
distribut
influenza
np
protein
cell
well
block
nuclear
export
np
imped
bind
np
meanwhil
bind
affect
np
dimer
format
impli
compound
multifunct
np
inhibitor
thu
find
present
studi
suggest
promis
compound
investig
use
strategi
iav
futur
author
confirm
conflict
interest
